Loading
A phase 2 trial of Rocapuldencel-T run by Argos Therapeutics, completed.
Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment is a phase 2 interventional study registered as NCT00678119 by Argos Therapeutics, with 25 participants enrolled, started 2008-01. Conditions recorded: Renal Cell Carcinoma. Interventions recorded: AGS-003 and Sunitinib.
Shares Rocapuldencel-T, Argos Therapeutics, Renal cell carcinoma and the tag pipeline.
Shares Rocapuldencel-T, Argos Therapeutics, Renal cell carcinoma and the tag pipeline.
Shares Rocapuldencel-T, Argos Therapeutics, Renal cell carcinoma and the tag pipeline.
Shares Rocapuldencel-T, Argos Therapeutics, Renal cell carcinoma and the tag pipeline.
Shares Rocapuldencel-T, Argos Therapeutics and the tag pipeline.
Shares Rocapuldencel-T, Argos Therapeutics and the tag pipeline.
Shares Renal cell carcinoma and the tag pipeline.
Shares Renal cell carcinoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/